BMPR1A sirna

BMPR1A siRNA (Human)

Cat. Num. AAA8216639

• Gene Names: BMPR1A; ALK3; SKR5; CD292; ACVRLK3; 10q23del
• Reactivity: Human
• Applications: RNA Interference (RNAi)
• Purity: > 97%
• Synonyms: BMPR1A; BMPR1A siRNA (Human); ACVRLK3; ALK3; Bone morphogenetic protein receptor type-1A; BMP type-1A receptor; BMPR-1A; Activin receptor-like kinase 3; ALK-3; Serine/threonine-protein kinase receptor R5; SKR5; CD antigen CD292; BMPR1A sirna

• Host: Synthetic
• Reactivity: Human
• Specificity: BMPR1A siRNA (Human) is a target-specific 19-23 nt siRNA oligo duplexes designed to knock down gene expression.
• Purity/Purification: > 97%
• Form/Format: Lyophilized powder
• Sequence Length: 532

• Applicable Applications for BMPR1A sirna: RNA Interference (RNAi)
• Quality Control: Oligonucleotide synthesis is monitored base by base through trityl analysis to ensure appropriate coupling efficiency. The oligo is subsequently purified by affinity-solid phase extraction. The annealed RNA duplex is further analyzed by mass spectrometry to verify the exact composition of the duplex. Each lot is compared to the previous lot by mass spectrometry to ensure maximum lot-to-lot consistency.
• Directions for Use: We recommends transfection with 100 nM siRNA 48 to 72 hours prior to cell lysis. Before resuspending, briefly centrifuge the tube to ensure the lyophilized siRNA is at the bottom of the tube. Resuspend the siRNA oligos to an appropriate concentration with DEPC water. For each vial, suitable for 250 transfections in 24 well plate (20 pmol for each well).
• Components: We offer pre-designed sets of 3 different target-specific siRNA oligo duplexes of human BMPR1A gene. Each vial contains 5 nmol of lyophilized siRNA. The duplexes can be transfected individually or pooled together to achieve knockdown of the target gene, which is most commonly assessed by qPCR or western blot. Our siRNA oligos are also chemically modified (2'-OMe) at no extra charge for increased stability and enhanced knockdown in vitro and in vivo.
• Preparation and Storage: Shipped at 4 degree C. Store at -20 degree C for one year.

Related Product Information for BMPR1A sirna

siRNA to inhibit BMPR1A expression using RNA interference

NCBI and Uniprot Product Information

• NCBI GI #: 41349437
• NCBI GeneID: 657
• NCBI Accession #: NP_004320.2
• NCBI GenBank Nucleotide #: NM_004329.2
• UniProt Accession #: P36894; Q8NEN8; A8K6U9
• Molecular Weight: 60,198 Da
• NCBI Official Full Name: bone morphogenetic protein receptor type-1A
• NCBI Official Synonym Full Names: bone morphogenetic protein receptor, type IA
• NCBI Official Symbol: BMPR1A
• NCBI Official Synonym Symbols: ALK3; SKR5; CD292; ACVRLK3; 10q23del
• NCBI Protein Information: bone morphogenetic protein receptor type-1A
• UniProt Protein Name: Bone morphogenetic protein receptor type-1A
• Protein Family: Bone morphogenetic protein receptor
• UniProt Gene Name: BMPR1A
• UniProt Synonym Gene Names: ACVRLK3; ALK3; BMP type-1A receptor; BMPR-1A; ALK-3; SKR5
• UniProt Entry Name: BMR1A_HUMAN

NCBI Description

The bone morphogenetic protein (BMP) receptors are a family of transmembrane serine/threonine kinases that include the type I receptors BMPR1A and BMPR1B and the type II receptor BMPR2. These receptors are also closely related to the activin receptors, ACVR1 and ACVR2. The ligands of these receptors are members of the TGF-beta superfamily. TGF-betas and activins transduce their signals through the formation of heteromeric complexes with 2 different types of serine (threonine) kinase receptors: type I receptors of about 50-55 kD and type II receptors of about 70-80 kD. Type II receptors bind ligands in the absence of type I receptors, but they require their respective type I receptors for signaling, whereas type I receptors require their respective type II receptors for ligand binding. [provided by RefSeq, Jul 2008]

Uniprot Description

BMPR1A: a serine/threonine-protein kinase receptor for Bone morphogenetic protein-2 and -4 (BMP-2 and BMP-4). Defects in BMPR1A are a cause of juvenile polyposis syndrome (JPS) and Cowden disease (CD), a cancer syndrome characterized by multiple hamartomas and by a high risk for breast, thyroid and endometriel cancers.

Protein type: Kinase, protein; Protein kinase, Ser/Thr (receptor); Membrane protein, integral; Protein kinase, TKL; EC 2.7.11.30; TKL group; STKR family; Type1 subfamily

Chromosomal Location of Human Ortholog: 10q22.3

Cellular Component: cell soma; dendrite; plasma membrane; integral to membrane; caveola

Molecular Function: transforming growth factor beta receptor activity; protein serine/threonine kinase activity; protein binding; protein homodimerization activity; metal ion binding; SMAD binding; transmembrane receptor protein serine/threonine kinase activity; ATP binding; receptor signaling protein serine/threonine kinase activity

Biological Process: neural plate mediolateral pattern formation; transcription from RNA polymerase II promoter; developmental growth; hindlimb morphogenesis; neural crest cell development; positive regulation of transcription, DNA-dependent; mesendoderm development; paraxial mesoderm structural organization; dorsal/ventral axis specification; palate development; protein amino acid phosphorylation; negative regulation of neurogenesis; BMP signaling pathway; transforming growth factor beta receptor signaling pathway; positive regulation of mesenchymal cell proliferation; ectoderm development; Mullerian duct regression; somitogenesis; in utero embryonic development; lateral mesoderm development; stem cell maintenance; positive regulation of bone mineralization; odontogenesis of dentine-containing teeth; positive regulation of osteoblast differentiation; mesoderm formation; pituitary gland development; cartilage development; embryonic organ development; immune response; embryonic digit morphogenesis; regulation of lateral mesodermal cell fate specification; positive regulation of epithelial cell proliferation; lung development

Disease: Juvenile Polyposis Syndrome; Polyposis Syndrome, Hereditary Mixed, 2